Recessive dystrophic epidermolysis bullosa is caused by biallelic pathogenic variants in the COL7A1 gene, located on chromosome 3. COL7A1 encodes type VII collagen, the primary constituent of anchoring fibrils that mechanically connect the basement membrane to the underlying dermis. Loss of functional type VII collagen results in skin fragility at the sub-lamina densa plane, explaining the characteristic blistering phenotype. The condition follows an autosomal recessive inheritance pattern. GeneReviews describes genotype-phenotype correlations within RDEB: severe RDEB is typically caused by biallelic null or out-of-frame variants resulting in absent functional protein, while intermediate RDEB generally results from variants that preserve some residual type VII collagen production. A subtypes registry encompasses at least one documented subtype, recessive dystrophic epidermolysis bullosa inversa, in addition to the generalized severe and intermediate forms.

The diagnosis of recessive dystrophic epidermolysis bullosa is suggested by clinical findings of skin fragility with blistering and milia formation healing with scarring, absent lingual papillae, and dystrophic or absent nails present from birth, as described in GeneReviews. Diagnostic confirmation involves molecular genetic testing to identify biallelic pathogenic or likely pathogenic variants in COL7A1, combined with electron microscopy demonstrating sub-lamina densa cleavage. GeneReviews notes that absent or reduced type VII collagen on immunofluorescence mapping of a skin biopsy supports the diagnosis. International clinical practice guidelines for DEB have been published by DEBRA International, providing comprehensive diagnostic frameworks covering skin biopsy, electron microscopy, immunofluorescence, and molecular genetic testing approaches. Genotype information contributes to subtype classification, with severe and intermediate subtypes distinguished by the nature and combination of COL7A1 variants identified.

Two FDA-approved disease-directed treatments are available for recessive dystrophic epidermolysis bullosa. Beremagene geperpavec-svdt (VYJUVEK), approved by the FDA in May 2023, and prademagene zamikeracel (zevaskyn), approved in April 2025, both hold regulatory authorization specifically for RDEB. GeneReviews describes RDEB-directed targeted therapies as those addressing the specific underlying mechanism of disease causation. DEBRA International has published international clinical practice guidelines encompassing multiple dimensions of RDEB management, including skin and wound care, treatment of anemia, oral health care, nutritional management, hand surgery and hand therapy, esophageal stricture care, cancer management, palliative and end-of-life care, neonatal care, occupational therapy, physical therapy, and psychosocial care. GeneReviews identifies several classes of agents and circumstances associated with worsening of RDEB, including nasogastric tubes (due to oral and esophageal fragility) and poorly fitting or coarse-textured clothing and footwear. Additional compounds carry orphan drug designation for RDEB, including angiotensin (1-7) designated specifically for treatment of RDEB.

The prognosis in recessive dystrophic epidermolysis bullosa is substantially influenced by subtype severity and the cumulative burden of cutaneous, mucosal, and extracutaneous complications over the course of the individual's lifetime. Infantile onset means that affected individuals carry the full burden of the disease from birth. Progressive scarring of the hands, esophageal strictures (present in 80–99% of individuals), chronic pain, and nutritional compromise are major sources of ongoing morbidity. Dilated cardiomyopathy represents an uncommon but serious cardiac complication. GeneReviews notes that squamous cell carcinoma is a recognized late complication of RDEB and is addressed within published cancer management guidelines. The approval of two disease-directed treatments—VYJUVEK (2023) and zevaskyn (2025)—represents a significant recent development in the therapeutic landscape for RDEB. GeneReviews documents reduced penetrance for dominant DEB; penetrance considerations for RDEB are distinct given the autosomal recessive inheritance.

The RDEB research landscape reflects active multidisciplinary investigation across molecular, clinical, and translational domains. A classified publication analysis identified 121 total publications, with case reports and case series as the dominant research type (26 case reports), alongside 22 reviews. Active research areas include gene therapy publications, biomarker studies, and recent clinical trial publications. Ten clinical trials are currently registered, including investigations targeting collagen VII antibodies in bullous diseases, biologic therapies, and drug therapy approaches. Academic and biotechnology sponsors active in RDEB trials include Abeona Therapeutics, Aegle Therapeutics, and Castle Creek Biosciences. The approval of two disease-directed therapies within the past three years reflects a period of substantial clinical development activity. Angiotensin (1-7) holds orphan drug designation specifically for treatment of RDEB, representing an additional compound under development for this indication. GeneReviews describes therapies under investigation within the dystrophic epidermolysis bullosa research context.